Thromb Haemost 1999; 82(01): 159-160
DOI: 10.1055/s-0037-1614654
Letters to the Editor
Schattauer GmbH

No Link between the TFPI V264M Mutation and Venous Thromboembolic Disease

Emmanuel Arnaud
1   From the INSERM U428 and Centre Claude Bernard de Recherche sur les Maladies Vasculaires, CHU Broussais, Paris, France
,
Didier Moatti
2   From the INSERM U479 and Service d’Hématologie et d’Immunologie, CHU Xavier Bichat, Paris, France
,
Joseph Emmerich
1   From the INSERM U428 and Centre Claude Bernard de Recherche sur les Maladies Vasculaires, CHU Broussais, Paris, France
,
Martine Aiach
1   From the INSERM U428 and Centre Claude Bernard de Recherche sur les Maladies Vasculaires, CHU Broussais, Paris, France
,
Dominique de Prost
2   From the INSERM U479 and Service d’Hématologie et d’Immunologie, CHU Xavier Bichat, Paris, France
› Author Affiliations
Further Information

Publication History

Received 17 February 1999

Accepted 27 April 1999

Publication Date:
11 December 2017 (online)

 

 
  • References

  • 1 Broze Jr GJ. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 1992; 29: 159-69.
  • 2 Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ. Cloning and characterisation of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001-4.
  • 3 Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 1997; 78: 471-7.
  • 4 Moatti D, Seknadji P, Galand C, Poirier O, Fumeron F, Desprez S, Garbarz M, Dhermy D, Arveiler D, Evans A, Luc G, Ruidavets J-B, Ollivier V, Hakim J, Aumont MC, de Prost D. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects. Impact of the V264M substitution on plasma levels of TFPI. Arterioscler Thromb Vasc Biol 1999; 19: 862-9.
  • 5 Alhenc-Gelas M, Arnaud E, Nicaud V, Aubry ML, Fiessinger JN, Aiach M, Emmerich J. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb Haemost 1999; 81: 506-10.